scholarly journals Advances in dynamic modeling of colorectal cancer signaling-network regions, a path toward targeted therapies

Oncotarget ◽  
2014 ◽  
Vol 6 (7) ◽  
pp. 5041-5058 ◽  
Author(s):  
Lorenzo Tortolina ◽  
David J. Duffy ◽  
Massimo Maffei ◽  
Nicoletta Castagnino ◽  
Aimée M. Carmody ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dynamic Modeling ◽  
Targeted Therapies ◽  
Signaling Network ◽  
Cancer Signaling

Novel and Emerging Targeted Therapies of Colorectal Cancer

2015 ◽  
Vol 10 (4) ◽  
pp. 279-298 ◽  
Author(s):  
Niklas Finnberg ◽  
Prashanth Gokare ◽  
Wafik El-Deiry
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapies

scholarly journals Identification of anticancer drug target genes using an outside competitive dynamics model on cancer signaling networks

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Tien-Dzung Tran ◽  
Duc-Tinh Pham
Keyword(s):  
Anticancer Drug ◽  
Drug Target ◽  
Target Genes ◽  
Signaling Network ◽  
Competitive Dynamics ◽  
Signaling Networks ◽  
Molecular Signaling ◽  
Dynamics Model ◽  
Cancer Signaling ◽  
The Impact

AbstractEach cancer type has its own molecular signaling network. Analyzing the dynamics of molecular signaling networks can provide useful information for identifying drug target genes. In the present study, we consider an on-network dynamics model—the outside competitive dynamics model—wherein an inside leader and an opponent competitor outside the system have fixed and different states, and each normal agent adjusts its state according to a distributed consensus protocol. If any normal agent links to the external competitor, the state of each normal agent will converge to a stable value, indicating support to the leader against the impact of the competitor. We determined the total support of normal agents to each leader in various networks and observed that the total support correlates with hierarchical closeness, which identifies biomarker genes in a cancer signaling network. Of note, by experimenting on 17 cancer signaling networks from the KEGG database, we observed that 82% of the genes among the top 3 agents with the highest total support are anticancer drug target genes. This result outperforms those of four previous prediction methods of common cancer drug targets. Our study indicates that driver agents with high support from the other agents against the impact of the external opponent agent are most likely to be anticancer drug target genes.

Current advances and trends in KRAS targeted therapies for colorectal cancer

2021 ◽  
pp. molcanres.0248.2021
Author(s):  
M.Y.M. Teo ◽  
J.Y. Fong ◽  
W.M. Lim ◽  
L.L.A. In
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapies

scholarly journals Discovery of molecular determinants of response to targeted therapies in colorectal cancer using patient-derived xenografts (‘xenopatients’)

2013 ◽  
Vol 7 (S2) ◽  
Author(s):  
Francesco Sassi ◽  
Giorgia Migliardi ◽  
Eugenia Zanella ◽  
Francesco Galimi ◽  
Francesca Cottino ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Targeted Therapies ◽  
Molecular Determinants

Systemic Therapy for Colorectal Cancer

2019 ◽  
Author(s):  
Anna M. Varghese
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Mismatch Repair ◽  
Targeted Therapies ◽  
Growth Factor Receptor ◽  
Braf V600e ◽  
Ongoing Research ◽  
Medical Oncologists ◽  
Epidermal Growth ◽  
Cytotoxic Therapies

Colorectal cancer remains the second most common cause of cancer-related deaths in this country. Although colorectal cancer is best managed by a multidisciplinary team of surgical, radiation, and medical oncologists, cytotoxic therapy remains the backbone of treatment in the metastatic disease setting. In addition to cytotoxic therapies, vascular-targeted therapies and epidermal growth factor receptor (EGFR)–targeted therapies for selected patients with metastatic colorectal cancer improve outcomes for patients with metastatic colorectal cancer. Growing understanding of various biological subsets of colorectal cancer, including BRAF V600E mutant and mismatch repair–deficient colorectal cancers, is expanding treatment opportunities for patients and is the focus of ongoing research. This review contains 4 tables and 57 references. Key Words: chemotherapy, colorectal cancer, fluoropyrimidines, immunotherapy, metastatic, mismatch repair–deficient colorectal cancer, targeted therapy, topoisomerase inhibitors

Cancers of the gastrointestinal tract

2010 ◽  
pp. 2405-2416
Author(s):  
J.A. Bridgewater ◽  
S.P. Pereira
Keyword(s):  
Colorectal Cancer ◽  
Gastrointestinal Tract ◽  
Targeted Therapies ◽  
Translational Medicine ◽  
Genetic Mechanisms

Cancers of the gastrointestinal tract are one of the most rewarding interfaces in translational medicine—particularly on colorectal cancer—leading to greater understanding of the genetic mechanisms leading to cancer and the development of novel targeted therapies. Diagnosis of gastrointestinal tract cancers is usually made or suspected at endoscopy, confirmed by biopsy....

Sign in / Sign up

Export Citation Format

Share Document